Filing Flows › Interpace Biosciences (IDXG) › Q4 2024
Interpace Biosciences (IDXG) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 31, 2025
Interpace Biosciences (IDXG) reported revenue of $12.4M for the fourth quarter 2024 (Q4 2024), +22% from a year earlier and +0.9% from the quarter before. Operating margin was 16.6%, net earnings $1.9M (15.2% of revenue).
Interpace Biosciences, Q4 2024: revenue $12.4M (+22% year over year), operating margin 16.6%, net earnings $1.9M, operating cash flow $1.2M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $12.4M | +0.9% | +22% |
| Gross profit | $7.9M | +0.1% | +25% |
| Operating profit | $2.1M | -10% | +38% |
| Net earnings | $1.9M | +12% | +76% |
| Operating cash flow | $1.2M | -44% | +4% |
| Free cash flow | $1.1M | -34% | +6% |
What changed
Revenue was $12.4M in Q4 2024, up 22% year over year and up 1% from the previous quarter.
Gross margin was 63.7%, up 1.4 points from a year earlier. Operating profit was $2.1M, a 16.6% margin (up 1.9 points year over year). Of the extra revenue versus a year earlier, 25% reached operating profit, above the 15% margin then. Operating expenses grew 21% against revenue growth of 22%. The fastest-growing cost line was General & admin (+39%). Net earnings were $1.9M, up 76% year over year. The effective tax rate was -0.4%.
Operating cash flow was $1.2M (up 4% year over year), 63% of net earnings. Non-cash charges added back $95K of depreciation and amortization and $73K of share-based compensation. Working capital and other items used $865K. Capital expenditures of $129K left free cash flow of $1.1M.
Questions
What was Interpace Biosciences' revenue in the fourth quarter 2024?
Interpace Biosciences (IDXG) reported revenue of $12.4M for the fourth quarter 2024 (Q4 2024), +22% from a year earlier and +0.9% from the quarter before.
Was Interpace Biosciences profitable in the fourth quarter 2024?
Operating profit was $2.1M (16.6% of revenue) and net earnings $1.9M.